Core Insights - Fosun Pharma (600196.SH) announced a licensing agreement with Expedition for the global development, production, and commercialization of the investigational product XH-S004, excluding mainland China and Hong Kong and Macau [1] - XH-S004 is a small molecule oral DPP-1 inhibitor aimed at reducing inflammation and preventing airway structural damage, with potential indications including non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments based on development and regulatory achievements, along with up to $525 million in sales milestone payments based on annual net sales in the licensed territories [1] Company Strategy - The collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally [1] - The agreement allows Fosun Pharma to maintain rights for the development, production, and commercialization of the product within mainland China and Hong Kong and Macau, thereby expanding its innovative product portfolio internationally [1]

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 海外監管公告 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月1 1 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 证券代码：600196 股票简称：复星医药 编号：临 2025-126 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司 ...

Core Insights - Fosun Pharma announced a licensing agreement with Expedition for the development, production, and commercialization of the investigational product XH-S004 outside of China and Hong Kong [2] - XH-S004 is a small molecule oral DPP-1 inhibitor that aims to reduce inflammation and block the cycle of infection and airway structural damage [2] - Potential indications for XH-S004 include non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [2] Financial Terms - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [2] - Additionally, Expedition may pay up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory [2]

（1）根据约定，Expedition将就本次合作向复星医药产业支付至多12,000万美元不可退还的首付款、开 发及监管里程碑付款，具体包括：①首付款1,700万美元；②根据许可产品于许可区域的临床试验及上 市进展等，支付至多10,300万美元的开发及监管里程碑款项。（2）此外，基于许可产品于许可区域的 年度净销售额（定义依约定）达成情况，由Expedition向复星医药产业依约支付至多52,500万美元的销 售里程碑款项。 格隆汇8月11日丨复星医药(600196.SH)公布，公司控股子公司复星医药产业与Expedition签订《许可协 议》，复星医药产业授予Expedition除中国境内及港澳地区以外的全球范围、许可领域内开发、生产及 商业化在研产品XH-S004的权利。本次合作后，本集团仍拥有许可产品于中国境内及港澳地区的开发、 生产及商业化权利。 XH-S004为本集团拥有自主知识产权的小分子口服DPP-1抑制剂，其通过抑制DPP-1及其激活的中性粒 细胞丝氨酸蛋白酶降低炎症反应，从而阻断感染恶性循环及由此导致的气道结构损伤。该在研药品的潜 在适应症包括非囊性纤维化支气管扩张症、慢性阻塞性肺疾病等。截至 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-126 上海复星医药（集团）股份有限公司 关于控股子公司签署许可协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●协议类型：开发、生产及商业化许可 ●协议内容：控股子公司复星医药产业授予 Expedition 于许可区域（即除中国 境内及港澳地区外的全球范围）及领域（即人类、动物疾病的诊断和治疗）开发、 生产及商业化在研产品 XH-S004 的权利。 ●特别风险提示： 1、许可产品于许可区域的临床、注册、生产（如有）、销售等还须得到相关监 管机构（包括但不限于美国 FDA、欧洲 EMA、日本 PMDA）的批准。根据国内外新药 研发经验，新药研发是项长期工作，需要经过临床试验、注册等诸多环节，具有不 确定性。因此，许可产品于许可区域相关临床试验能否完成以及能否获得上市批准， 存在不确定性。 2、于本次合作中所约定的开发及监管里程碑款项，须以约定的临床进展、注册 上市进程等作为触发条件。因此，复星医药产业实际收取的开发及监管里程碑款项， 须根 ...

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Expedition for the development, production, and commercialization of the investigational product XH-S004 outside of China and Hong Kong, while retaining rights for these regions [1] Group 1: Licensing Agreement Details - The agreement grants Expedition global rights to develop and commercialize XH-S004, excluding China and Hong Kong [1] - Fosun Pharma retains the rights to develop, produce, and commercialize the product within China and Hong Kong [1] Group 2: Product Information - The investigational drug XH-S004 has potential indications for non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease (COPD) [1] Group 3: Financial Terms - Expedition will pay up to $120 million in non-refundable upfront payments to Fosun Pharma [1] - Additional payments will be made based on development and regulatory milestones [1] - Up to $525 million in sales milestone payments will be contingent on annual net sales performance of the licensed product in the designated regions [1]

中国经济网北京8月11日讯复星医药（600196）(600196.SH)昨晚发布关于为控股子公司提供担保的进展 公告。截至2025年8月8日，包括本次担保在内，复星医药实际对外担保金额折合人民币约2,393,074万 元，约占2024年12月31日集团经审计的归属于上市公司股东净资产的50.64%；均为公司与控股子公司/ 单位之间、控股子公司/单位之间发生的担保。 2025年8月7日，健嘉医疗与交通银行签订《保证合同三》，约定由健嘉医疗为其间接控股子公司西安健 嘉于2025年3月17日至2029年3月17日期间与交通银行所签订的不超过人民币1,100万元的融资主合同项 下债务提供最4高额连带责任保证担保，每笔债务的保证期间为自该笔债务约定的履行期限届满之日起 至全部融资主合同项下最后到期的主债务履行期限届满之日后三年止。西安健嘉将抵押其部分自有设施 设备为前述担保提供反担保。 | 对外担保逾期的累计金额 | 人民币 0元 | | --- | --- | | 裁至2025年8月8日,包括本次担保在 内,本集团实际对外担保金额 | 折合人民币约 2.393.074 万元 | | 对外担保金额占 2024年12月 ...

Group 1 - Tsinghua Unigroup's control will change as Hunan Sailuxian will acquire approximately 58.61 million shares from its controlling shareholder, Tsinghua Technology Service Co., Ltd, leading to a shift in control of Tsinghua Unigroup [1] - The new controlling shareholder will need to stabilize the company's operations amidst industry consolidation, and investors should pay attention to future asset integration and the new shareholder's resource injection capabilities, with potential short-term stock price volatility [1] Group 2 - Shuoshi Bio reported a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year, primarily due to the deepening of centralized procurement in the in vitro diagnostic industry and an increase in the VAT rate to 13% [2] - The decline in net profit is attributed to pressure on product prices from industry procurement, a significant drop in gross margin, and a 13.11% reduction in R&D investment, which may weaken long-term competitiveness [2] Group 3 - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech, received FDA approval to conduct Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic cancer, marking a significant step in the internationalization of innovative drugs [3] - The drug's dual advantages of immune modulation and precise targeting position it competitively in the global market, with the potential to fill a treatment gap for thymic cancer if subsequent data is positive [3] Group 4 - Junshi Biosciences announced that the National Medical Products Administration has accepted the application for the 13th indication of its PD-1 monoclonal antibody, Toripalimab, for use in combination with HER2 ADC for patients with locally advanced or metastatic urothelial carcinoma expressing HER2 [4] - This combination is expected to further strengthen Junshi's differentiated positioning in the PD-1 market and enhance collaboration with Rongchang Bio on ADC development [4]

Group 1 - The company has completed the issuance of the second phase of technology innovation bonds for the year 2025, with a registered amount of RMB 40 billion, valid for two years from March 20, 2025 [1][2] - The first phase of medium-term notes was issued in April 2025, totaling RMB 5 billion [1] - The company’s affiliate, Fosun United Health Insurance Co., Ltd., participated in the subscription of the second phase of debt financing tools, with a final allocation of RMB 30 million [1] Group 2 - On August 7, 2025, the company’s subsidiary, Nantong Jianjia, signed a loan agreement with Nantong Rural Commercial Bank for RMB 20 million, with a loan term from July 23, 2025, to December 21, 2028 [6] - The company provided a joint liability guarantee for the loan, with a guarantee period of three years after the loan repayment deadline [6][10] - The company has approved a total guarantee limit of RMB 35,048 million, which includes guarantees for its subsidiaries [11][30] Group 3 - As of August 8, 2025, the total amount of external guarantees provided by the group is approximately RMB 23,930 million, accounting for 50.64% of the net assets attributable to shareholders as of December 31, 2024 [30] - There are no overdue guarantee matters as of the same date [31]

Group 1 - The company has completed the issuance of the second phase of technology innovation bonds for the year 2025, with a total registered amount of RMB 40 billion, valid for two years from March 20, 2025 [1][2] - The first phase of medium-term notes was issued in April 2025, totaling RMB 5 billion [1] - The company’s affiliate, Fosun United Health Insurance Co., Ltd., participated in the subscription of the second phase of debt financing tools, with a final allocation amount of RMB 30 million [1] Group 2 - On August 7, 2025, the company’s subsidiary, Nantong Jianjia, signed a loan agreement with Nantong Rural Commercial Bank for RMB 20 million, with a loan term from July 23, 2025, to December 21, 2028 [6] - The company provided a joint liability guarantee for the loan, with a guarantee period of three years after the debt performance period [6][12] - The company has also signed several guarantee contracts for its subsidiaries, including a maximum joint liability guarantee for RMB 5.5 million and RMB 11 million for other subsidiaries [7][19] Group 3 - As of August 8, 2025, the total external guarantee amount by the group is approximately RMB 23.93 billion, accounting for 50.64% of the net assets attributable to shareholders as of December 31, 2024 [31] - There are no overdue guarantee matters as of the same date [31]